Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained remission in patients with early axSpA.C-OPTIMISE was a two-part, multicentre phase 3b study in adults with early active axSpA (radiographic or...